FAQs

Frequently Asked Questions


Dravya Discovery provides preclinical in vitro research services focused on ophthalmology drug discovery and early translational research. Our services include human cell-based disease models, assay development, target validation, mechanistic studies, and efficacy testing across a range of ocular indications.

We support research across multiple ophthalmic indications, including:

  • Age-related macular degeneration (AMD)
  • Diabetic retinopathy
  • Retinal degeneration
  • Glaucoma
  • Dry eye disease
  • Corneal inflammation and fibrosis
  • Uveitis
  • Ocular inflammation

We can also develop custom disease models tailored to specific research questions.

We use human-relevant cell-based models to replicate key disease mechanisms in the eye. These may include:

  • Primary ocular cells
  • Immortalized cell lines
  • Co-culture models
  • Inflammation models
  • Fibrosis models
  • Barrier function assays
  • Retinal and corneal cell systems

These models help evaluate drug efficacy, mechanism of action, and safety signals early in the discovery process.

Yes. In addition to established assays, we frequently develop bespoke experimental models and assays designed around specific drug targets, pathways, or therapeutic mechanisms.

Our scientists work closely with clients to ensure the assay captures relevant disease biology and delivers actionable data.

We support testing across a wide range of therapeutic modalities including:

  • Small molecules
  • Biologics
  • Antibodies
  • Peptides
  • Gene therapy vectors
  • RNA therapeutics

Our assays can be adapted to evaluate mechanism, potency, and functional activity for these modalities.

Depending on the study design, we can measure:

  • Cytokine and inflammatory marker release
  • Barrier integrity and permeability
  • Cell viability and cytotoxicity
  • Fibrosis markers
  • Gene expression (qPCR)
  • Protein expression (ELISA, multiplex assays)
  • Imaging-based cellular responses

Functional activity assays

Project timelines vary depending on complexity, but typical timelines are:

  • Standard assays: 2–4 weeks
  • Custom assay development: 4–8 weeks
  • Complex disease models: 6–12 weeks

We provide clear project timelines and milestones at the proposal stage.

We follow rigorous experimental practices including:

  • Standardised protocols
  • Biological and technical replicates
  • Appropriate positive and negative controls
  • Statistical analysis of results
  • Transparent reporting of methods and data

Our goal is to deliver high-confidence, decision-ready datasets.

We encourage close collaboration. Clients typically receive:

  • A study plan prior to project initiation
  • Regular project updates
  • Final study report with full data analysis

Opportunity to discuss results directly with our scientists

Yes. Many of our projects involve confidential early-stage therapeutic programmes. We routinely work under NDAs and strict confidentiality agreements to ensure client IP protection.

Yes. Our clients include biotech companies, pharmaceutical companies, academic groups, and venture-backed start-ups working on innovative ophthalmology therapeutics.

To begin a collaboration:

  1. Contact us through our Request a Quote form or email.
  2. Share a brief description of your project requirements.
  3. Our scientific team will propose a study design and quotation.
  4. Once approved, we schedule the project and begin experimental work.